Pharsight

Turalio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8722702 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(3 years from now)

US9169250 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(3 years from now)

US8404700 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(3 years from now)

US7893075 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
May, 2033

(9 years from now)

US10730876 DAIICHI SANKYO INC Synthesis of a compound that modulates kinases
May, 2036

(12 years from now)

US9802932 DAIICHI SANKYO INC Solid forms of a compound modulating kinases
May, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461169 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity
Apr, 2028

(3 years from now)

US9358235 DAIICHI SANKYO INC Kinase modulation, and indications therefor
Jun, 2033

(9 years from now)

US10189833 DAIICHI SANKYO INC Solid forms of a compound modulating kinases
May, 2036

(12 years from now)

US10435404 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(14 years from now)

US10941142 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(14 years from now)

US10961240 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(14 years from now)

Turalio is owned by Daiichi Sankyo Inc.

Turalio contains Pexidartinib Hydrochloride.

Turalio has a total of 12 drug patents out of which 0 drug patents have expired.

Turalio was authorised for market use on 14 October, 2022.

Turalio is available in capsule;oral dosage forms.

Turalio can be used as treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

Drug patent challenges can be filed against Turalio from 03 August, 2023.

The generics of Turalio are possible to be released after 24 July, 2038.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-250) Aug 02, 2026
New Chemical Entity Exclusivity(NCE) Aug 02, 2024
ODE*(ODE*) Aug 02, 2026

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

NCE-1 date: 03 August, 2023

Market Authorisation Date: 14 October, 2022

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL

More Information on Dosage

TURALIO family patents

Family Patents